These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12372512)

  • 41. NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists.
    Yuan J; Chen X; Brodbeck R; Primus R; Braun J; Wasley JW; Thurkauf A
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2715-8. PubMed ID: 9873609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Residues at the indole-NH of LE300 modulate affinities and selectivities for dopamine receptors.
    Robaa D; Kretschmer R; Siol O; Abulazm SE; Elkhawass E; Lehmann J; Enzensperger C
    Arch Pharm (Weinheim); 2011 Jan; 344(1):28-36. PubMed ID: 21213349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N-(1-Benzylpyrrolidin-3-yl)arylbenzamides as potent and selective human dopamine D4 antagonists.
    Egle I; Barriault N; Bordeleau M; Drage J; Dube L; Peragine J; Mazzocco L; Arora J; Jarvie K; Tehim A
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4847-50. PubMed ID: 15341937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
    Kolasa T; Matulenko MA; Hakeem AA; Patel MV; Mortell K; Bhatia P; Henry R; Nakane M; Hsieh GC; Terranova MA; Uchic ME; Miller LN; Chang R; Donnelly-Roberts DL; Namovic MT; Hollingsworth PR; Martino B; El Kouhen O; Marsh KC; Wetter JM; Moreland RB; Brioni JD; Stewart AO
    J Med Chem; 2006 Aug; 49(17):5093-109. PubMed ID: 16913699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR.
    Grundt P; Husband SL; Luedtke RR; Taylor M; Newman AH
    Bioorg Med Chem Lett; 2007 Feb; 17(3):745-9. PubMed ID: 17095222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels.
    Carling RW; Moore KW; Moyes CR; Jones EA; Bonner K; Emms F; Marwood R; Patel S; Patel S; Fletcher AE; Beer M; Sohal B; Pike A; Leeson PD
    J Med Chem; 1999 Jul; 42(14):2706-15. PubMed ID: 10411491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor.
    Liégeois JF; Bruhwyler J; Damas J; Rogister F; Masereel B; Geczy J; Delarge J
    Eur J Pharmacol; 1995 Feb; 273(3):R1-3. PubMed ID: 7737323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
    Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A structure-affinity relationship study on derivatives of N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a high-affinity and selective D(4) receptor ligand.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 2000 Jan; 43(2):270-7. PubMed ID: 10649982
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human D2 and D4 dopamine receptors couple through betagamma G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively.
    Pillai G; Brown NA; McAllister G; Milligan G; Seabrook GR
    Neuropharmacology; 1998 Aug; 37(8):983-7. PubMed ID: 9833627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds.
    Ishizumi K; Kojima A; Antoku F; Saji I; Yoshigi M
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2139-51. PubMed ID: 8582016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis, docking and pharmacological evaluation of novel homo- and hetero-bis 3-piperazinylpropylindole derivatives at SERT and 5-HT1A receptor.
    Pessoa-Mahana H; González-Lira C; Fierro A; Zapata-Torres G; Pessoa-Mahana CD; Ortiz-Severin J; Iturriaga-Vásquez P; Reyes-Parada M; Silva-Matus P; Saitz-Barría C; Araya-Maturana R
    Bioorg Med Chem; 2013 Dec; 21(24):7604-11. PubMed ID: 24262884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Azaindole derivatives with high affinity for the dopamine D4 receptor: synthesis, ligand binding studies and comparison of molecular electrostatic potential maps.
    Löber S; Hübner H; Gmeiner P
    Bioorg Med Chem Lett; 1999 Jan; 9(1):97-102. PubMed ID: 9990464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extended N-Arylsulfonylindoles as 5-HT₆ Receptor Antagonists: Design, Synthesis & Biological Evaluation.
    Vera G; Lagos CF; Almendras S; Hebel D; Flores F; Valle-Corvalán G; Pessoa-Mahana CD; Mella-Raipán J; Montecinos R; Recabarren-Gajardo G
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27537868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.
    Bettinetti L; Schlotter K; Hübner H; Gmeiner P
    J Med Chem; 2002 Oct; 45(21):4594-7. PubMed ID: 12361386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chiral indolo[3,2-f][3]benzazecine-type dopamine receptor antagonists: synthesis and activity of racemic and enantiopure derivatives.
    Robaa D; Enzensperger C; Eldin Abulazm S; Hefnawy MM; El-Subbagh HI; Wani TA; Lehmann J
    J Med Chem; 2011 Oct; 54(20):7422-6. PubMed ID: 21888437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines .
    Rondu F; Le Bihan G; Wang X; Lamouri A; Touboul E; Dive G; Bellahsene T; Pfeiffer B; Renard P; Guardiola-Lemaitre B; Manechez D; Penicaud L; Ktorza A; Godfroid JJ
    J Med Chem; 1997 Nov; 40(23):3793-803. PubMed ID: 9371245
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
    Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
    J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.
    Austin NE; Avenell KY; Boyfield I; Branch CL; Hadley MS; Jeffrey P; Johnson CN; Macdonald GJ; Nash DJ; Riley GJ; Smith AB; Stemp G; Thewlis KM; Vong AK; Wood MD
    Bioorg Med Chem Lett; 2001 Mar; 11(5):685-8. PubMed ID: 11266169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.